SCHEMBL3228455

SCHEMBL3228455

CN1CCN(c2ccccc2F)c2ccc(OC(F)(F)F)cc2C1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.40
P2RY1 P47900 4/20 0.40
OPRL1 P41146 1/20 0.38
KCNH2 Q12809 2/20 0.38
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
CCR6 P51684 1/20 0.38
TRPV4 Q9HBA0 2/20 0.37
HTR2A P28223 1/20 0.37
DRD1 P21728 1/20 0.37
DRD5 P21918 1/20 0.37
SLC6A2 P23975 6/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ADRA1A P35348 1/20 0.35
NPY5R Q15761 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3479773 0.88 ALDH1A1 (0.40) ALDH1A1OPRL1KCNH2DRD2DRD3
SCHEMBL3233898 0.87 ALDH1A1 (0.42) ALDH1A1P2RY1KCNH2DRD2DRD3
SCHEMBL3227350 0.86 DRD1 (0.51) DRD2DRD3DRD1DRD5SLC6A2
SCHEMBL3479737 0.85 KCNH2 (0.44) ALDH1A1KCNH2DRD2DRD3CCR6
SCHEMBL3479570 0.85 HTR1A (0.40) ALDH1A1P2RY1KCNH2DRD2DRD3
SCHEMBL3479544 0.82 ALDH1A1 (0.40) ALDH1A1KCNH2DRD2DRD3TRPV4
SCHEMBL3233430 0.82 TRPV4 (0.42) ALDH1A1KCNH2DRD2DRD3TRPV4
SCHEMBL3479806 0.82 ALDH1A1 (0.41) ALDH1A1KCNH2DRD2DRD3TRPV4
SCHEMBL3479706 0.81 SCN9A (0.45) ALDH1A1KCNH2DRD2DRD3HTR2A
SCHEMBL3231984 0.81 DRD2 (0.43) ALDH1A1KCNH2DRD2DRD3TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D ALDH1A1 372/4885P2RY1 298/4885OPRL1 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.